Cohort Study of Chronic Heart Failure
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Analyze Etiology, Comorbidities, Clinical Characteristics
- Sponsor
- Xiang Xie
- Enrollment
- 20000
- Primary Endpoint
- cardiac marker
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.
Detailed Description
Inclusion criteria: 1. Accompanied by difficulty breathing, fatigue, or decreased activity tolerance; 2. Signs of fluid retention (pulmonary congestion and peripheral edema); 3. Echocardiography shows abnormalities in cardiac structure and/or function; 4. Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L. 5. HF hospitalization recorded within the previous 12 months Exclusion criteria: 1. Concomitant severe liver function, renal failure, or other severe system dysfunction 2. Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.
Investigators
Xiang Xie
professor
Xinjiang Medical University
Eligibility Criteria
Inclusion Criteria
- •Accompanied by difficulty breathing, fatigue, or decreased activity tolerance;
- •Signs of fluid retention (pulmonary congestion and peripheral edema);
- •Echocardiography shows abnormalities in cardiac structure and/or function;
- •Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L.
Exclusion Criteria
- •Concomitant severe liver function, renal failure, or other severe system dysfunction
- •Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.
Outcomes
Primary Outcomes
cardiac marker
Time Frame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
CK，CK-MB，cTnT，cTnI，Mb
serum biochemical indicators
Time Frame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
HDL-cholesterol, mg/dL，LDL-cholesterol, mg/dL，Total cholesterol, mg/dL，Triglycerides, mg/dL
echocardiogram
Time Frame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
ejection fraction,Consider heart failure when the ejection fraction is less than 50%
Secondary Outcomes
- Thyroid Function(Follow up will be conducted at baseline, 6 months, 12 months, and 36 months)
- Coagulation function indicators(Follow up will be conducted at baseline, 6 months, 12 months, and 36 months)
- Blood routine(Follow up will be conducted at baseline, 6 months, 12 months, and 36 months)